Kirkland Advises Cinven on Sale of Minority Stake in SYNLAB to Labcorp
Kirkland & Ellis has advised Cinven on the sale of an indirect minority stake in SYNLAB to strategic investor Labcorp. The completion of the sale is subject to regulatory approvals and is expected to occur in Q1 2025.
SYNLAB is one of the leading European clinical laboratory and medical diagnostic services companies and has more than 27,000 employees in over 30 countries across four continents. The company achieved revenues of €2.64 billion in 2023. Kirkland already advised Cinven on the public acquisition offer and re-investment of co-investors in 2023 and the subsequent delisting of SYNLAB AG in 2024.
Labcorp is a global leader of innovative and comprehensive laboratory services headquartered in the United States. The company has more than 60,000 employees worldwide.
The Kirkland team advising Cinven was led by transactional partners Dr. Ben Leyendecker and Dr. Christoph Jerger and associate Dr. Marcus Commandeur.
